Table 1.
Baseline Characteristics.
| Characteristics | D-TACE-C group(N = 27) (No, %; Mean ± SD) |
C-TACE-C Group (N = 27) (No, %; Mean ± SD) |
P value |
|---|---|---|---|
| Gender | .715 | ||
| Male | 23 (85.2%) | 22 (81.5%) | |
| Female | 4 (14.8%) | 5 (18.5%) | |
| Age (years) | 53.5 ± 10.6 | 52.7 ± 11.8 | .809 |
| ECOG performance | .402 | ||
| 0 | 15 (55.6%) | 18 (66.7%) | |
| 1 | 12 (44.4%) | 9 (33.3%) | |
| BCLC stage | 1 | ||
| B | 9 (33.3%) | 9 (33.3%) | |
| C | 18 (66.7%) | 18 (66.7%) | |
| Hepatitis | .551 | ||
| Hepatitis B | 20 (74.1%) | 18 (66.7%) | |
| Other | 7 (25.9%) | 9(33.3%) | |
| Child-pugh class | .685 | ||
| A | 24 (88.9%) | 23 (85.2%) | |
| B | 3 (11.1%) | 4 (14.8%) | |
| TB (µmol/L) | 16.0 ± 8.0 | 18.3 ± 12.8 | .441 |
| Albumin (g/L) | 37.6 ± 7.4 | 37.0 ± 4.6 | .717 |
| PT(s) | 14.0 ± 1.4 | 13.9 ± 1.1 | .674 |
| AST (µmol/L) | 86.1 ± 101.6 | 56.0 ± 39.7 | .161 |
| ALT (µmol/L) | 54.9 ± 67.3 | 44.4 ± 28.9 | .449 |
| PLR | 155.3 ± 77.0 | 144.0 ± 95.3 | .634 |
| NLR | 3.6 ± 1.9 | 2.8 ± 2.0 | .210 |
| Tumor size (cm) | 9.4 ± 3.6 | 9.4 ± 5.9 | .971 |
| TACE sessions | 4.2 ± 1.8 | 4.0 ± 1.9 | .617 |
| Tumor number | .143 | ||
| ≤3 | 6 (22.2%) | 11 (40.7%) | |
| >3 | 21 (77.8%) | 16 (59.3%) | |
| α-Fetoprotein level | .276 | ||
| ≥400 ng/mL | 12 (44.4%) | 16 (59.3%) | |
| <400 ng/ml | 15 (55.6%) | 11 (40.7%) | |
| Ascites | .552 | ||
| Absent | 25 (92.6%) | 26 (96.3%) | |
| Present | 2 (7.4%) | 1 (3.7%) | |
Note. D-TACE-C: drug-eluting beads transarterial chemoembolization plus camrelizumab; C-TACE-C: conventional transarterial chemoembolization plus camrelizumab; SD: Standard deviation; ECOG: Eastern Cooperative Oncology Group; TB: Total bilirubin; PT: Prothrombin time; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio;